Drug
WR 279 clinical trials
- studies test it
- 8
- open now
- 0
- in phase 3
- 2
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 6
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 8
U.S. Army Medical Research and Development Command (7) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses WR 279 is read from its arms, and is right about nine times in ten.
Testing it · 8
- Safety, Efficacy, and PK of Topical Paromomycin/Gentamicin Cream for Treatment of Cutaneous LeishmaniasisTerminatedPhase 2U.S. Army Medical Research and Development CommandNCT01140191Written as WR 279,396
- Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in PanamaCompletedPhase 3U.S. Army Medical Research and Development CommandNCT01790659Written as WR 279,396
- Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old WorldCompletedPhase 2U.S. Army Medical Research and Development CommandNCT00703924Written as WR 279,396
- WR 279,396 for the Treatment of Cutaneous LeishmaniasisCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT01988909Written as WR 279,396
- Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)CompletedPhase 2U.S. Army Medical Research and Development CommandNCT01032382Written as WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
- Pharmacokinetics, Safety, and Efficacy Trial of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream for the Treatment of Cutaneous Leishmaniasis in PanamaCompletedPhase 2U.S. Army Medical Research and Development CommandNCT01083576Written as WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
- WR 279,396 Open Label Treatment Protocol in TunisiaTerminatedPhase 2U.S. Army Medical Research and Development CommandNCT01494350Written as WR 279,396 topical cream
- Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)CompletedPhase 3U.S. Army Medical Research and Development CommandNCT00606580Written as WR 279,396 topical cream